| SLE (n = 66) |
---|---|
Baseline laboratory findings | |
 Total leukocytes (N cells/mm3, median (IQR)) | 7.0 (4.5–9.1) |
 Total lymphocytes (N cells/mm3, median (IQR)) | 0.9 (0.5–1.4) |
 CD19 positive cells (n = 37) (N cells/mm3/percentage median (IQR)) | 0.05 (0.03–0.12)/7.0 (4.0–13.0) |
 Anti-dsDNA positivity, (n, %) | 44 (66.7) |
 Low complement levels (n = 61), (n, %) | 35 (57.4) |
Primary indication for RTX | |
 Lupus nephritis, n (%) | 42 (63.6) |
 Neurolupus, n (%) | 7 (10.6) |
 Lupus related arthritis, n (%) | 7 (10.6) |
 Mucocutaneous manifestations, n (%) | 2 (3.0) |
 Haematological manifestations, n (%) | 5 (7.6) |
 Other manifestationsa, n (%) | 3 (4.5) |
Ongoing treatment at RTX initiation | |
 Oral Prednisolone, n (%) | 61 (92.4), |
 Daily dose, mg (median (IQR)) | 12.5 (12.5–20.0) |
 Antimalarials, n (%) | 27 (40.9) |
 Azathioprine, n (%) | 6 (9.1) |
 Mycophenolate, n (%) | 9 (13.6) |
 Methotrexate, n (%) | 3 (4.5) |
Previous treatments | |
 Cyclophosphamide, n (%) | 40 (60.6) |
 Cumulative dose (median (IQR)) | 6075 (3150–9275) |
 Azathioprine, n (%) | 44 (66.7) |
 Mycophenolate, n (%) | 32 (48.5) |
 Methotrexate, n (%) | 17 (25.8) |
 Cyclosporine A, n (%) | 11 (16.7) |